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Introduction
Systemic juvenile idiopathic arthritis (SJIA), an
interleukin-1b (IL-1b)-mediated autoinflammatory
disease, is characterized by recurrent flares of active
disease. Treatment with canakinumab (CAN), a selective,
human, anti-IL-1b monoclonal antibody allows for suc-
cessful steroid dose reduction/discontinuation and reduces
risk to experience a flare in patients with SJIA [1]. CAN is
approved for SJIA patients (≥ 2 years old) by over
30 countries including USA, EU, Russia and Canada.
Objectives
To evaluate the maintenance of efficacy with continued
CAN treatment in SJIA patients during the blinded ran-
domized treatment withdrawal part of a large phase III
trial.
Methods
Patients 2–19 yrs of age with active SJIA who had
responded to open-label CAN treatment 4mg/kg/4wks sc,
maintained a minimum adapted ACR Pediatric criteria
[aACR] 30 for up to 32 weeks, and were steroid-free or
had successfully reduced systemic steroids to a minimum
dose, were randomized to either continue CAN or receive
placebo until 37 flare events occurred [1]. Patients were
considered to have completed the study if they entered
clinical remission on medication (CRM), i.e. achieved 24
consecutive weeks of clinical inactive disease (CID) [2]. A
survival analysis of the time to worsening in aACR level,
after randomization for the CAN and placebo groups
was performed. Time to worsening is the time to fail to
maintain at least the same level of aACR response seen at
randomization. The change in the proportion in each
group of those with CID was also evaluated.
Results
100 pts were randomized to a CAN (n=50) or a placebo
(n=50) group, of whom 26 (53%) and 27 (54%), respec-
tively, had CID at the start of the randomization part. In
the first 2 months, probability of maintaining aACR
response was similar for both treatment groups. There-
after, the probability of maintaining aACR response was
greater in the CAN vs placebo groups. The median time
to worsening in aACR level for patients in the placebo
group was 141 days (95% CI: 85, 281), and could not be
calculated for CAN as <50% of CAN group had a wor-
sening in their aACR level by the end of this phase. The
median duration of exposure for the CAN group was
221.5 days (range: 8-617 days). There was a statistically
significant relative risk reduction of 51% for the CAN vs
placebo group to experience a worsening in aACR level
(HR= 0.49; 95% CI: 0.27, 0.90; p=0.0131). CID was
achieved by 31(62.0%) vs 17 (34.0%) patients in CAN vs
placebo at their last visit (OR= 3.4; 95% CI: 1.5, 8.0;
p=0.0020) and CRM was reached by 20 (40%) CAN and
2 (4%) placebo patients by the end of the study.
Conclusion
A greater proportion of SJIA patients who continued
CAN treatment maintained/improved their aACR
response, achieved CID and CRM than patients who
discontinued CAN by being switched to placebo,
demonstrating maintenance of efficacy with continued
CAN treatment over time.
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